{
    "organizations": [],
    "uuid": "b4e7b882a22e36711469ebadca2a4c6da5fa4d16",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-wilson-with-promising-preliminary/brief-wilson-with-promising-preliminary-long-term-data-idUSFWN1RP023",
    "ord_in_thread": 0,
    "title": "BRIEF-Wilson with Promising Preliminary Long Term Data",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 12 (Reuters) - Wilson Therapeutics AB:\n* TERM DATA FOR WTX101 IN WILSON DISEASE PRESENTED AT EASL ANNUAL MEETING\n* SAYS ONCE-DAILY TREATMENT WITH WTX101 SIGNIFICANTLY REDUCES FREE COPPER LEVELS IN PATIENTS WITH WILSON DISEASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-12T13:34:00.000+03:00",
    "crawled": "2018-04-13T17:37:00.017+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "wilson",
        "therapeutic",
        "ab",
        "term",
        "data",
        "wtx101",
        "wilson",
        "disease",
        "presented",
        "easl",
        "annual",
        "meeting",
        "say",
        "treatment",
        "wtx101",
        "significantly",
        "reduces",
        "free",
        "copper",
        "level",
        "patient",
        "wilson",
        "disease",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}